title: Improvement in social competence in patients with schizophrenia: a pilot study using a performance-based measure using virtual reality.
abstract: OBJECTIVE
  The objective of this study was to explore the possibility of the use of Virtual Reality Functional Skills Assessment (VRFSA) in a future regular clinical trial, as well as to report a preliminary result about effectiveness of atypical antipsychotics to social competence in schizophrenia.
  
  
  METHODS
  We developed the VRFSA that measured subjects' performances automatically and used analogue scale rather than Likert scale. Twenty-four female patients with paranoid schizophrenia and 15 healthy females were recruited. This was a 6-week, randomized, open-label, and flexible dose study, and 2 treatments (baseline versus post-treatment) x 2 skills phases (receptive versus expressive) x 2 patient groups (aripiprazole versus risperidone) analysis of variance was used in the final analysis.
  
  
  RESULTS
  There was a significant difference in the VRFAS between the patients and the healthy subjects (p < 0.05). Eighteen patients were included in the final analysis. We found larger treatment effect than those found in previous studies, and significant treatment x skills phase x group interaction effect on the VRFAS.
  
  
  CONCLUSIONS
  Our results suggest that the VRFAS is strongly sensitive to changes in social competence and thus especially beneficial in short-term clinical trials. In addition, atypical antipsychotics can improve social competence and differentially improve receptive skills and expressive skills in schizophrenia.
authors: Severance Mental Health Hospital, 696-6 Tanbeol-dong, Gwangju-si, Gyeonggi-do 464-100, Korea.
authors: Kyung-Min
authors: KM
authors: Park
authors: Jeonghun
authors: J
authors: Ku
authors: Il-Ho
authors: IH
authors: Park
authors: Ji-Yeon
authors: JY
authors: Park
authors: Sun I
authors: SI
authors: Kim
authors: Jae-Jin
authors: JJ
authors: Kim
mesh_terms: D000293:Adolescent; D000328:Adult; D000704:Analysis of Variance; D014150:Antipsychotic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000068180:Aripiprazole; D003936:Diagnosis, Computer-Assisted / Q000379:methods*; D005260:Female; D006801:Humans; D008875:Middle Aged; D010865:Pilot Projects; D010879:Piperazines / Q000494:pharmacology / Q000627:therapeutic use; D015363:Quinolones / Q000494:pharmacology / Q000627:therapeutic use; D018967:Risperidone / Q000494:pharmacology / Q000627:therapeutic use; D012563:Schizophrenia, Paranoid / Q000188:drug therapy* / Q000503:physiopathology; D012565:Schizophrenic Psychology; D012720:Severity of Illness Index; D012919:Social Behavior; D014584:User-Computer Interface; D055815:Young Adult
chemical_list: D014150:Antipsychotic Agents; D010879:Piperazines; D015363:Quinolones; D000068180:Aripiprazole; D018967:Risperidone